Merck's Keytruda plus chemo comes up short as post-surgery therapy in newly diagnosed endometrial cancer
While Merck & Co.’s Keytruda already boasts a pair of approvals to treat certain forms of endometrial cancer, a recent effort to prove the PD-1 inhibitor’s worth as a post-surgery add-on therapy in newly diagnosed patients has fallen short. Adjuvant …